https://www.selleckchem.com/pr....oducts/alkbh5-inhibi
akeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints. Acceptability and feasibility of the BPaL regimen is high among TB stakeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints. Antimicrobial resistance is a global health emergency. Persons colonized with
Like
Comment
Share
